Effect of a new de- N-acetyl-lysoglycosphingolipid on some tumour models

• Published in: European journal of pharmacology Vol. 294; no. 2; pp. 555 - 563
• Main Authors: Tubaro, Ezio, Borelli, Giorgio P., Belogi, Luisella, Cavallo, Giovanni, Santoni, Angela, Mainiero, Fabrizio
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 29.12.1995; Elsevier
• Subjects: Adhesion; Animals; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; Carbohydrate Sequence; Cell Division - drug effects; Chemotherapy; Gangliosides - pharmacology; Glycosphingolipid; Humans; Male; Medical sciences; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Neoplasms, Experimental - drug therapy; Peritumoral; Pharmacology. Drug treatments; Recombinant interleukin-2; Tumor; Tumor Cells, Cultured; Tumor; Peritumoral; Glycosphingolipid; Adhesion; Recombinant interleukin-2; Drug combination; Rodentia; Malignant tumor; In vitro; Biological activity; Fibronectin; In vivo; Vertebrata; Chemotherapy; Mammalia; Laminin; Treatment; Interleukin 2; Mouse; Animal; Tumor cell

A new de- N-acetylated glycosphingolipid termed WILD20, a breakdown product of GM 1 obtained through alkaline hydrolysis, and characterized by nuclear magnetic resonance, mass spectrometry and elementary analysis, was found to inhibit phospholipase A 2 via phosphokinase C translocation blockade. The...